RS Research, a clinically-validated biotechnology company developing targeted oncology therapies with a focus on improved safety and efficacy, announced that an abstract presenting the Phase 1a clinical trial results of its lead candidate, RS_0139, has been accepted for online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL. […]

“Women Innovators” Prize in the leading category of the European Prize for Women Innovators program was awarded to RS Research Co-Founder Prof. Rana Sanyal for her successful work in the field of biotechnology. […]

Designing drug candidates with a superior therapeutic index, RS Research will advance to the next dose cohort following the positive review of the safety data from the dosing of the first cohort by the Independent Data Monitoring Committee (IDMC). Medical experts of IDMC recommended […]

RS Research announced that the first patient has been dosed in the Phase I clinical trial evaluating the safety of RS-0139 in NSCLC. RS Research’s pipeline is based on the proprietary platform technology Sagitta^©, which are nanocarriers with versatile targeting capability and suitable […]

Clinical-stage biotechnology start-up developing smart nanomedicines in oncology raised $12 Million at Series-A Round with investors GEN, OneLife and Eczacıbaşı Momentum. This funding will help the company gain speed in the clinical development of its portfolio as well as become […]

RS Research was named one of the “5 Top Nanomedicine Startups Impacting The Healthcare Industry” by StartUs Insights

Technology focused venture capital fund ACT Venture Partners, whose main investor is European Investment Fund, has invested 1.1 million Euros in nanomedicine start-up RS Research. The company began developing drug candidates with improved efficacy and reduced side effect […]